By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Quest Diagnostics has licensed rights from Health Discovery Corp. and privately held firm Smart Personalized Medicine to develop laboratory tests that help determine appropriate breast cancer therapies.

The firms did not provide details on the licensed technologies. Under the terms of the agreements, Quest will pay health Discovery and SPM upfront licensing payments, development fees, and royalties on a per test basis.

Further terms were not disclosed.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Genome Research this week: mitochondrial and nuclear gene fusions in cancer, role of genomic imprinting in tissue-specific gene expression, and more.

Maria Freire from the Foundation for the NIH calls for "politically popular pledges of support" for the NIH to turn into support for increased funding for the agency.

A Thomson Reuters analysis indicates that the life sciences, rather than the tech sector, are increasingly driving global innovation.

The White House says ethical discussions about genome editing of the human germline are needed.